Abstract: Provided herein are binding polypeptides that specifically bind DLL3. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific contracts and chimeric antigen receptors, that bind DLL3. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided DLL3 binding polypeptides for treating diseases and conditions, such as cancer.

Abstract: One or more quorum silencing enzymes entrapped in an organopolysiloxane matrix, formulations comprising the enzymes, methods for obtaining the entrapped enzymes by co-gelation and methods of treating intestinal diseases.

Abstract: 2-Naphthalene sulfonate salt forms of Compound (I), compositions containing those salt forms, and methods of preparation thereof are described herein. The use of the 2-naphthalene sulfonate salt forms of Compound (I), and associated compositions, for the treatment of diseases, disorders and conditions are also described.

Abstract: Synthetic human cell mimic hydrogel particles and their use in cytometric or coulter device applications are described. The synthetic human cell mimic hydrogel particles described herein are selectively tunable to have at least one optical, volumetric, or capacitance property that is substantially similar to a corresponding optical, volumetric, or capacitance property of the human cell mimic hydrogel particle's natural biological cell counterpart.

Abstract: Provided herein are methods of treating cancer with a combination of a DR5 agonist and a PLK1 inhibitor. Also provided herein are methods of treating cancer with a combination of a DR5 agonist and a CDK inhibitor.

Abstract: Disclosed are novel urokinase plasminogen activator receptor (uPAR) binding molecules and soluble urokinase plasminogen activator receptor (suPAR) binding molecules and methods of their use.

Abstract: The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.

Abstract: Systems are provided that provide an extended measuring range for biological assays, such as immunoassays. In one embodiment a plurality of discrete test sites is used. Data for the proportion of test sites that indicate the presence of the analyte of interest and data that provides a statistical value for a signal generated by the population of discrete test sites is gathered. The results of these digital and statistical approaches are aggregated to provide an extended dynamic range.

Abstract: In one embodiment, a system includes a flow cell assembly having a flow cell body with a base having an opening allowing sheathed sample fluid to flow out, a bracket coupled to the flow cell body, a flat mirror mounted to the bracket, a hardware triggered camera coupled to the bracket on one side, and a diffused light emitting diode strobe light coupled to the bracket on an opposite side. The camera and strobe light are pointed at the mirror on opposite sides. Activation of the diffused LED strobe light generates a diffused strobe light into the mirror backlighting a droplet stream. Triggering of the camera is synchronized with the generation of the strobe light to periodically capture a brightfield still image of the droplet stream. The image can be analyzed for measured jet breakoff point and measured droplet interval point for visual feedback control of the droplet stream.

Abstract: Provided herein, in some aspects, are binding molecules including co-binders having high affinity and/or high specificity to a target.

Abstract: A pharmaceutically acceptable salt of an acyclic nucleotide phosphoramidate to treat HPV and related conditions including neoplasia, as well as pharmaceutical compositions, morphic forms and dosage forms thereof.

Abstract: Provided herein are VHH-containing polypeptides that bind OX40. In some embodiments, VHH-containing polypeptides that bind and agonize OX40 are provided. Uses of the VHH-containing polypeptides are also provided.

Abstract: Provided herein are compositions, methods, kits, and devices for the treatment of skin diseases. Also provided herein are isolated and purified bacteria, excipients, carriers, dosage forms and routes of administration for such bacteria. Furthermore, provided herein are isolated and purified mixtures of bacteria, excipients, carriers, dosage forms and routes of administration for such mixtures. Also provided herein are conditions for treatment with bacteria and bacterial mixtures.

Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, components of the multispecific polypeptides are connected by a non-cleavable linker. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.

Abstract: The present disclosure relates to compositions comprising a plurality of modified particles that allow for one-pot calibration, compensation, and spectral unmixing, and methods for their use.

Abstract: A biological fluid filtration system for scanning a biological fluid so as to filter potentially undesirable constituents from the biological fluid for therapeutic or diagnostic purposes. The biological fluid filtration system generally includes a fluid receiving device adapted to receive a biological fluid. A valve including an inlet, a first outlet, and a second outlet is fluidly connected to the fluid receiving device. The biological fluid within the fluid receiving device is scanned by a scanner to produce scanned data relating to the biological fluid. A control unit in communication with the scanner and the valve receives the scanned data and controls the valve based on the scanned data. The valve is controlled to direct the biological fluid through either the first or second outlet of the valve depending upon the constituents of the biological fluid identified by the control unit.

Abstract: The present disclosure provides feeder hydrogel particles that can function to support the growth, proliferation, and/or activation of a target cell in culture. The present disclosure also provides methods of culturing target cells with feeder hydrogel particles.

Abstract: The invention relates to the field of molecular biology and recombinant nucleic acid technology. In particular, the invention relates to a method of treating a patient with Duchenne Muscular Dystrophy comprising the removal of at least one exon from the dystrophin gene using engineered nucleases.

Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.

Abstract: The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within the human PCSK9 gene. The present invention also encompasses methods for using such engineered meganucleases in a pharmaceutical composition and in methods for treating or reducing the symptoms of cholesterol-related disorders, such as hypercholesterolemia. Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating cholesterol-related disorders, such as hypercholesterolemia.